Replies to post #171 on Corvus Pharmaceuticals Inc (CRVS)

[jxphilli]

For anyone that doesn't know, this is outrageous for a red day. Just an FYI

[BooDog]

Insiders taking advantage of the surge...
https://ih.advfn.com/stock-market/NASDAQ/corvus-pharmaceuticals-CRVS/stock-news/86116048/statement-of-changes-in-beneficial-ownership-4

Thinking we may see a few more form 4's.


So what
Corvus is currently testing mupadolimab as both a monotherapy and as part of a combination treatment in two early-stage trials for various solid tumors. Investors, for their part, seem to think that this experimental CD73 antibody might attract either a lucrative licensing deal or perhaps a full-on buyout in the wake of Astra's impressive midstage trial results. Now, the interesting part of this story is that this hypothesis could actually have some truth behind it. Big pharma has shown a keen interest in early-stage oncology assets of late, especially ones with a novel mechanism of action such as mupadolimab.

Now what
Is Corvus stock worth buying on this pullback? While speculative, this small-cap biotech may indeed be worth the risk. Astra, and several other big pharmas, have long been on the hunt for agents to boost the efficacy of their checkpoint inhibitors in several hard-to-treat cancers. So it wouldn't be surprising in the least if one or more of these pharma giants approached Corvus about a partnership soon.

That being said, there are no guarantees that a deal will materialize, meaning that investors may want to keep their starter position on the small side for the time being.
https://www.fool.com/investing/2021/09/22/why-corvus-pharmaceuticals-stock-is-down-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article